Lupin partners with Celnova Pharma to distribute NaMuscla in Argentina and Colombia
NaMuscla (mexiletine) to be commercialised for the treatment of non-dystrophic myotonic disorders in adults
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Orphan Drug
Lupin signs distribution agreement with Medis for orphan drug NaMuscla
The agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic…
Eton Pharma gets US FDA approval for orphan drug ALKINDI SPRINKLE (hydrocortisone)
It is indicated as replacement therapy in paediatric patients with adrenocortical insufficiency
FDA approves Tecartus, cell-based gene therapy to treat relapsed or refractory MCL in adults
It also received ‘Orphan Drug’ designation, which provides incentives to assist and encourage the development of drugs for rare…
Lupin signs distribution agreement in EU territories for orphan drug NaMuscla
Reportedly, NaMuscula is the first and only licensed product for myotonia in adults with non-dystrophic myotonic disorders
DCGI gives limited approval to market Stempeutics’ allogeneic cell therapy
Stempeucel is used in the treatment of Buerger’s disease